Trial Updates

Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD 4:37
Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD
Daniel Corcos • 23 Sep 2021
The impact of LCIG on dyskinesia duration & severity in PD 4:19
The impact of LCIG on dyskinesia duration & severity in PD
Alfonso Fasano • 22 Sep 2021
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD 3:11
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD
Celia Oreja-Guevara • 14 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
Daridorexant: a breakthrough for insomnia treatment in Europe? 5:10
Daridorexant: a breakthrough for insomnia treatment in Europe?
Diego Garcia-Borreguero • 30 Sep 2021
Dual orexin receptor antagonists – the story so far and daridorexant Phase III data 17:01
Dual orexin receptor antagonists – the story so far and daridorexant Phase III data
Diego Garcia-Borreguero • 30 Sep 2021
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world 1:56
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
Piero Barbanti • 27 Sep 2021
Inflammatory microRNA levels associate with worse disability in MS 2:47
Inflammatory microRNA levels associate with worse disability in MS
Bárbara Guerra Leal • 8 Oct 2021
Triheptanoin: targeting the Krebs cycle in Huntington’s disease 8:36
Triheptanoin: targeting the Krebs cycle in Huntington’s disease
Fanny Mochel • 24 Sep 2021
The efficacy of amantadine as an early add-on for motor complications 3:15
The efficacy of amantadine as an early add-on for motor complications
Caroline Tanner • 14 Sep 2021
Learnings from laquinimod in MS 2:31
Learnings from laquinimod in MS
Giancarlo Comi • 28 Sep 2021
The story of laquinimod in multiple sclerosis 4:11
The story of laquinimod in multiple sclerosis
Giancarlo Comi • 28 Sep 2021
Stroke care in Brazil 5:55
Stroke care in Brazil
Sheila Martins • 21 Sep 2021
Current treatments for primary and secondary progressive multiple sclerosis 4:46
Current treatments for primary and secondary progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
SPHYNCS: an observational study for the discovery of markers of the narcoleptic borderland disorders 4:57
SPHYNCS: an observational study for the discovery of markers of the narcoleptic borderland disorders
Claudio Bassetti • 23 Sep 2021
The content of VJNeurology is intended for healthcare professionals